 |
市場調查報告書
商品編碼
1535587
東莨菪鹼市場 - 按劑型（經皮貼片、片劑、注射）、應用（暈動病、術後噁心嘔吐）、給藥途徑（局部、口服、腸胃外）、配銷通路- 全球預測（2024 - 2032）Scopolamine Market - By Dosage Form (Transdermal Patches, Tablets, Injectables), Application (Motion Sickness, Postoperative Nausea and Vomiting), Route of Administration (Topical, Oral, Parenteral), Distribution Channel - Global Forecast (2024 - 2032) |
||||||
在該領域合作研究不斷增加的推動下，2024 年至 2032 年間，全球東莨菪鹼市場複合年成長率將達到 5.3%。東莨菪鹼是一種抗膽鹼能藥物，主要用於其止吐和抗膽鹼能特性，由於其超越傳統用途的潛在應用而受到高度關注。製藥公司、學術機構和研究組織之間的合作研究正在擴大對東莨菪鹼在治療各種疾病（包括暈動病、術後噁心，甚至某些神經系統疾病）方面的功效和安全性的了解。
這些研究工作正在帶來新的臨床試驗、創新配方和增強的輸送系統，從而推動市場成長。整合多學科方法來研究東莨菪鹼的機制和治療效果，正在加速先進療法的開發。隨著這些合作產生了可喜的成果，市場對東莨菪鹼療法的需求不斷增加，反映出利用聯合專業知識推進醫療治療和改善患者治療效果的更廣泛趨勢。
東莨菪鹼產業的整體價值根據劑型、應用、給藥途徑、配銷通路和地區進行分類。
從劑型來看，2024年至2032年，東莨菪鹼片劑市場收入將實現令人稱讚的複合年成長率。東莨菪鹼片以其治療暈動病和術後噁心的功效而聞名，為其他給藥方法提供了一種非侵入性替代方案。人們對口服藥物的日益偏好，加上片劑技術的進步，正在推動市場成長。片劑延長的保存期限和穩定性進一步增強了它們的吸引力。隨著消費者和醫療保健提供者尋求可靠且方便用戶使用的治療選擇，對東莨菪鹼片的需求持續成長。
在應用方面，從2024年到2032年，術後噁心部分將出現顯著成長。東莨菪鹼具有抗膽鹼能特性，可有效緩解噁心和嘔吐，使其成為術後護理的寶貴選擇。它能夠以各種形式（包括貼片和片劑）給藥，增強了其多功能性和吸引力。隨著醫療保健提供者專注於改善術後患者的預後，對東莨菪鹼作為控制術後噁心的可靠治療方法的需求持續上升，支持了其市場成長。
2024年至2032年，歐洲東莨菪鹼市場將呈現顯著的複合年成長率。貼片和片劑等各種製劑的可用性提高了患者的依從性和可及性。此外，人們對東莨菪鹼益處的認知和研究的增加也導致其需求不斷成長。歐洲監管部門的批准和臨床研究進一步支持市場擴張。隨著對患者舒適度和有效症狀管理的關注不斷加強，東莨菪鹼在歐洲醫療保健領域的作用不斷增強。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 由於慢性病而進行的外科手術數量不斷增加
- 藥物輸送系統的進步
- 暈車和噁心的盛行率增加
- 產業陷阱與挑戰
- 副作用和安全問題
- 替代療法的可用性
- 成長動力
- 成長潛力分析
- 報銷場景
- 監管環境
- 技術景觀
- 核心技術
- 鄰近技術
- 2023 年定價分析
- 按地區
- 按關鍵人物
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按劑型，2021 - 2032
- 主要趨勢
- 經皮貼劑
- 平板電腦
- 注射劑
- 其他劑型
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 暈車
- 術後噁心嘔吐（PONV）
- 其他應用
第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年
- 主要趨勢
- 專題
- 口服
- 注射用
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Alchem International Pvt. Ltd.
- Australian Alkaloids Ltd.
- Baxter International Inc.
- Caleb Pharmaceuticals, Inc.
- Fine Chemicals Corporation
- Fresenius SE & Co. KGaA
- GSK plc
- Ingenus Pharmaceuticals
- Mylan N.V.
- Myungmoon Pharm. Co., Ltd.
- Novartis AG
- Perrigo Company plc
- Pfizer Inc.
- Phytex Australia
- Teva Pharmaceutical Industries Limited
Global Scopolamine Market will witness 5.3% CAGR between 2024 and 2032, fueled by increasing collaborative research in the field. Scopolamine, an anticholinergic drug used primarily for its antiemetic and anticholinergic properties, is seeing heightened interest due to its potential applications beyond traditional uses. Collaborative research among pharmaceutical companies, academic institutions, and research organizations is expanding the understanding of Scopolamine's efficacy and safety in treating various conditions, including motion sickness, postoperative nausea, and even certain neurological disorders.
These research efforts are leading to new clinical trials, innovative formulations, and enhanced delivery systems, driving market growth. The integration of multidisciplinary approaches in studying Scopolamine's mechanisms and therapeutic benefits is accelerating the development of advanced treatments. As these collaborations yield promising results, the market is experiencing increased demand for scopolamine-based therapies, reflecting the broader trend of leveraging joint expertise to advance medical treatments and improve patient outcomes.
The overall Scopolamine Industry value is classified based on the dosage form, application, route of administration, distribution channel, and region.
Based on dosage form, the scopolamine market revenue from the tablets segment will register a commendable CAGR from 2024 to 2032. Tablets offer a convenient and precise dosage form, enhancing patient compliance and ease of use. Scopolamine tablets, known for their effectiveness in treating motion sickness and postoperative nausea, provide a non-invasive alternative to other delivery methods. The growing preference for oral medications, coupled with advancements in tablet technology, is driving market growth. Tablets' extended shelf life and stability further contribute to their appeal. As consumers and healthcare providers seek reliable and user-friendly treatment options, the demand for scopolamine tablets continues to rise.
In terms of application, the postoperative nausea segment will witness an appreciable growth from 2024 to 2032. This condition, a common complication following surgical procedures, significantly impacts patient comfort and recovery. Scopolamine, with its anticholinergic properties, provides effective relief from nausea and vomiting, making it a valuable option for postoperative care. Its ability to be administered in various forms, including patches and tablets, enhances its versatility and appeal. As healthcare providers focus on improving postoperative patient outcomes, the demand for Scopolamine as a reliable treatment for managing postoperative nausea continues to rise, supporting its market growth.
Europe Scopolamine market will exhibit a notable CAGR from 2024 to 2032. European healthcare providers and patients increasingly seek effective and non-invasive treatment options, boosting Scopolamine's popularity. The availability of various formulations, such as patches and tablets, enhances patient compliance and accessibility. Additionally, increased awareness and research into Scopolamine's benefits contribute to its rising demand. European regulatory approvals and clinical studies further support market expansion. As the focus on patient comfort and effective symptom management intensifies, Scopolamine's role in the European healthcare landscape continues to grow.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing number of surgical procedures due to chronic diseases
- 3.2.1.2 Advancements in drug delivery systems
- 3.2.1.3 Increasing prevalence of motion sickness and nausea
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects and safety concerns
- 3.2.2.2 Availability of alternative therapies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Reimbursement scenario
- 3.5 Regulatory landscape
- 3.6 Technological landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
- 3.7 Pricing analysis, 2023
- 3.7.1 By region
- 3.7.2 By key player
- 3.8 Future market trends
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Transdermal patches
- 5.3 Tablets
- 5.4 Injectables
- 5.5 Other dosage forms
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Motion sickness
- 6.3 Postoperative nausea and vomiting (PONV)
- 6.4 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Topical
- 7.3 Oral
- 7.4 Parenteral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Alchem International Pvt. Ltd.
- 10.2 Australian Alkaloids Ltd.
- 10.3 Baxter International Inc.
- 10.4 Caleb Pharmaceuticals, Inc.
- 10.5 Fine Chemicals Corporation
- 10.6 Fresenius SE & Co. KGaA
- 10.7 GSK plc
- 10.8 Ingenus Pharmaceuticals
- 10.9 Mylan N.V.
- 10.10 Myungmoon Pharm. Co., Ltd.
- 10.11 Novartis AG
- 10.12 Perrigo Company plc
- 10.13 Pfizer Inc.
- 10.14 Phytex Australia
- 10.15 Teva Pharmaceutical Industries Limited
